Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PRECISION BIOSCIENCES INC (DTIL)

Precision BioSciences reports PBGENE-HBV Phase 1 data, selects 0.4 mg/kg dose for Phase 2

Positive Impact 3 of 5 other Written later

Precision BioSciences released updated Phase 1 ELIMINATE-B data for PBGENE-HBV, its gene editing candidate for chronic hepatitis B, ahead of a late-breaking presentation at AASLD The Liver Meeting 2026. The company selected 0.4 mg/kg as the go-forward dose and plans a global Phase 2 study, with dosing expected to begin in the first quarter of 2027. The filing contains no financial results, so the update is clinical and early-stage for shareholders.

Key points

  • As of the September 28, 2026 data cutoff, 25 patients had received 59 administrations across four dose levels.
  • 11 of 12 evaluable patients with detectable pgRNA at baseline reached undetectable pgRNA, including all six at 0.4 mg/kg.
  • One delayed ALT/AST elevation at 0.4 mg/kg reached a peak ALT of 306 U/L and resolved without intervention.
  • Investor webcast is scheduled for Monday, November 9, 2026 at 8:00 a.m. ET.

The filing

CompanyPRECISION BIOSCIENCES INC (DTIL)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:01 AM ET
Accession number0001628280-26-070542

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.